Compare RRGB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | ACET |
|---|---|---|
| Founded | 1969 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.4M | 77.3M |
| IPO Year | 2002 | 2017 |
| Metric | RRGB | ACET |
|---|---|---|
| Price | $5.86 | $7.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $9.00 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 475.6K | 91.3K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $0.46 |
| 52 Week High | $7.52 | $9.47 |
| Indicator | RRGB | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 73.25 | 48.77 |
| Support Level | $3.94 | $7.70 |
| Resistance Level | $7.52 | $8.68 |
| Average True Range (ATR) | 0.40 | 0.54 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 92.07 | 31.79 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).